Oldest pages

Jump to navigation Jump to search

Showing below up to 50 results in range #3,751 to #3,800.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. The Coronavirus Structure and Host (Section from DOI: 10.1080/09273948.2020.1738501)‏‎ (18:34, 14 May 2020)
  2. Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:05, 14 May 2020)
  3. Section 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:08, 14 May 2020)
  4. Section 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:08, 14 May 2020)
  5. Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:09, 14 May 2020)
  6. Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:09, 14 May 2020)
  7. Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:10, 14 May 2020)
  8. Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:10, 14 May 2020)
  9. Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:11, 14 May 2020)
  10. Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:11, 14 May 2020)
  11. Section 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:12, 14 May 2020)
  12. Disclosure statement (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:13, 14 May 2020)
  13. Section 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:14, 14 May 2020)
  14. Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:17, 14 May 2020)
  15. Section 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:18, 14 May 2020)
  16. Section 2.2: Isolation and protection requirements (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:18, 14 May 2020)
  17. Section 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:19, 14 May 2020)
  18. Section 3: Diagnosis and treatment of SARS-CoV-2 infected patients (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:19, 14 May 2020)
  19. Section 3.1: Screening criteria (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:20, 14 May 2020)
  20. Section 3.2: Diagnostic criteria (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:20, 14 May 2020)
  21. Section 3.3: Examination routines of SARS-CoV-2 infected patient (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:21, 14 May 2020)
  22. Section 3.3.1: Screening cases on the day of visit (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:21, 14 May 2020)
  23. Section 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:22, 14 May 2020)
  24. Section 3.4: Place of treatment according to the severity of the disease (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:23, 14 May 2020)
  25. Section 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:24, 14 May 2020)
  26. Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:24, 14 May 2020)
  27. Section 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265)‏‎ (19:24, 14 May 2020)
  28. World Health Organization cited as Ref 2 in DOI: 10.1080/22221751.2020.1735265‏‎ (12:16, 17 May 2020)
  29. Li T, et al, Chin Med J (Engl) (2003) cited as Ref 3 in DOI: 10.1080/22221751.2020.1735265‏‎ (12:16, 17 May 2020)
  30. Tai-sheng LI, et al, Chin J Lab Med (2003) cited as Ref 4 in DOI: 10.1080/22221751.2020.1735265‏‎ (12:16, 17 May 2020)
  31. Taoran G, et al, Chin J Internal Med (2020) cited as Ref 5 in DOI: 10.1080/22221751.2020.1735265‏‎ (12:16, 17 May 2020)
  32. Mori I, et al, PLoS One (2008) cited as Ref 6 in DOI: 10.1080/22221751.2020.1735265‏‎ (12:16, 17 May 2020)
  33. Hemming VG., et al, Clin Diagn Lab Immunol (2001) cited as Ref 7 in DOI: 10.1080/22221751.2020.1735265‏‎ (12:16, 17 May 2020)
  34. National Health Commission cited as Ref 1 in DOI: 10.1080/22221751.2020.1735265‏‎ (12:33, 17 May 2020)
  35. Pengfei Shi (2nd author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  36. Gaichao Zhao (3rd author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  37. Jie Xu (4th author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  38. Wen Peng (5th author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  39. Jiayi Zhang (6th author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  40. Guanghui Zhang (7th author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  41. Xiaowen Wang (8th author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  42. Zhen Dong (9th author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  43. Fei Chen (10th author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  44. Hongjuan Cui (11th author of 10.1038/s41392-020-0110-5)‏‎ (15:29, 19 May 2020)
  45. Liqun Yang (1st author of 10.1038/s41392-020-0110-5)‏‎ (15:38, 19 May 2020)
  46. Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (21:46, 19 May 2020)
  47. Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:46, 20 May 2020)
  48. Section 3.2.7: PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:46, 20 May 2020)
  49. Siegel RL, et al. CA Cancer J. Clin. (2019) cited as Ref 1 in DOI: 10.1038/s41392-020-0110-5‏‎ (14:59, 20 May 2020)
  50. Sun Y, et al. Med. Res. Rev. (2015) cited as Ref 2 in DOI: 10.1038/s41392-020-0110-5‏‎ (14:59, 20 May 2020)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:AncientPages"